CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma

References

• Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma--diagnosis and treatment. Lancet Oncol 2004;5:19–26.
   PubMed Web of Science ®Google Scholar
• Björkholm M, Axdorph U, Grimfors G, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Ann Oncol 1995;6:895–899.
   PubMed Web of Science ®Google Scholar
• Smithers DW. Summary of papers delivered at the conference on staging in Hodgkin's disease (Ann Arbor). Cancer Res 1971;31:1869–1870.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Sup SJ, Alemañy CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005;23:3773–3779.
   PubMed Web of Science ®Google Scholar
• Diepstra A, van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007;25:3101–3108.
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al. Topoisomerase II alpha expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 2008;14:1759–1766.
   PubMed Web of Science ®Google Scholar
• Kelley TW, Pohlman B, Elson P, et al. The ratio of FOXP3 + regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007;128:958–965.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvadó MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467–1473.
   PubMed Web of Science ®Google Scholar
• Blum KA. Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2010:93–100.
   Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605–612.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–2174.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362: 875–885.
   PubMed Web of Science ®Google Scholar
• DeVita VT Jr. A breakthrough in Hodgkin's disease. Nat Rev Clin Oncol 2010;7:179.
   PubMed Web of Science ®Google Scholar
• Diehl V. Hematology. Are macrophages the bad guys in Hodgkin lymphoma?. Nat Rev Clin Oncol 2010;7:301–302.
   PubMed Web of Science ®Google Scholar
• Azambuja D, Natkunam Y, Biasoli I, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012;23:736–742.
   PubMed Web of Science ®Google Scholar
• Benedicte D, Emmanuel B, Vincent R, et al. Macrophages and mast cells infiltration are biomarkers of primary refractory Hodgkin's lymphoma. Blood 2010;116(Suppl. 1): Abstract 3881.
   Google Scholar
• Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Hematol 2012;88:292–305.
   PubMed Web of Science ®Google Scholar
• Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269–276.
   PubMed Web of Science ®Google Scholar
• Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013;31:256–262.
   PubMed Web of Science ®Google Scholar
• Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies. Ann Oncol 2007;18(Suppl. 9):ix71–ix79.
   PubMedGoogle Scholar
• Ganesan P, Kumar L, Raina V, et al. Hodgkin's lymphoma--long-term outcome: an experience from a tertiary care cancer center in north india. Ann Hematol 2011;90:1153–1160.
   PubMed Web of Science ®Google Scholar
• De Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg lymphoma biomarker consortium. J Clin Oncol 2007;25:805–812.
   PubMed Web of Science ®Google Scholar
• Pulford KA, Sipos A, Cordell JL, et al. Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol 1990;2:973–980.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549–555.
   PubMed Web of Science ®Google Scholar
• Sánchez-Aguilera A, Montalbán C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662–668.
   PubMed Web of Science ®Google Scholar